J&J Taking The Long View With Its Therapeutic Franchises
This article was originally published in The Pink Sheet Daily
Executive Summary
The Big Pharma has only recently entered the diabetes drug market, but has plans to make a significant impact on how the disease is treated. During a meeting with analysts, J&J highlighted the deals it’s made and the multiple indications it will pursue within the metabolic space.